Cocrystal Pharma selected two lead antiviral drug candidates for COVID-19 oral drug program
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for…
Biotechnology | Cartoons - Original | CRISPR | Disease | Genomics | Life Science History | Therapeutics
Evolution of CRISPR
The Evolution of CRISPR illustrates its climb out of the primordial ocean on the backs of eukaryotic cells…
‘Ultrapotent’ antibodies neutralized SARS-CoV-2 variants in NIAID study
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
Oral immunotherapy induced remission of peanut allergy in some young children
On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health found that giving peanut…
Merck and Ridgeback announced supply agreement with UNICEF for molnupiravir, investigational oral antiviral COVID-19 medicine
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
Positive results of Pfizer’s phase 3 study exploring co-administration of PREVNAR 20 with Pfizer-BioNTech COVID-19 vaccine released
On Jan. 12, 2022, Pfizer announced positive top-line results from a Phase 3 study describing the safety and…
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | FDA | Life Science History | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 heroes & Remembrance
Our Heroes and Remembrance illustration has Maurice Ralph Hilleman and John Enders, pioneering developers of common vaccines, and…
Merck and Ridgeback’s molnupiravir, an investigational oral antiviral COVID-19 treatment, received special approval for emergency in Japan
On Dec. 24, 2021, Merck and Ridgeback Biotherapeutics announced that Japanï¾’s Ministry of Health, Labor and Welfare had…
Merck and Ridgeback’s molnupiravir received U.S. FDA EUA for treatment of high-risk adults with COVID-19
On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) had…
Pfizer and BioNTech submit updated longer-term follow-up data of COMIRNATY in adolescents to EMA
On Dec. 23, 2021, Pfizer and BioNTech announced that they had submitted longer-term follow-up data from the companiesï¾’…
Gilead announced NEJM publication of data demonstrating Veklury (Remdesivir) significantly reduced risk of hospitalization in patients with COVID-19
On Dec. 22, 2021, Gilead Sciences announced full results from a Phase 3 investigational study evaluating the efficacy…
Cocrystal Pharma’s COVID-19 oral and intranasal/pulmonary protease inhibitors exhibited powerful in vitro potency against the SARS-CoV-2 Omicron variant
On Dec. 22, 2021, Cocrystal Pharma announced that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main…
Oxford team published blueprint for making millions of doses of a new vaccine within 100 days
On Dec. 21, 2021, the University of Oxford’s vaccine manufacturing research team published a pre-print paper demonstrating the…
Pfizer and BioNTech provided EU more than 200 million additional doses of COMIRNATY for vaccine supply
On Dec. 20, 2021, Pfizer and BioNTech announced an agreement had been reached with the European Commission (EC)…
Pfizer announced additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate
On Dec. 14, 2021, Pfizer announced final results from an analysis of all 2,246 adults enrolled in its…
CytoDyn submited protocol with FDA for phase 3 Registrational trial of leronlimab for critically ill COVID-19 population
On Dec. 9, 2021, CytoDyn announced that it had submitted a Phase 3, randomized, double blind, placebo controlled…
Pfizer and BioNTech provided update on Omicron variant
On Dec. 8, 2021, Pfizer and BioNTech announced results from an initial laboratory study demonstrating that serum antibodies…
Sorrento announced publication of novel SARS-CoV-2 main protease inhibitors for potential treatment of COVID-19 patients infected with SARS-CoV-2
On Dec. 5, 2021, Sorrento Therapeutics announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors…
SIGA announced Health Canada regulatory approval of Oral TPOXX
On Dec. 1, 2021, SIGA Technologies announced that Health Canada had approved oral TPOXX (tecovirimat) as an extraordinary…
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Life Science History | Medicine | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 roller coaster
The COVID-19 Roller Coaster is a wild ride, strap yourself in and hold on… Cast of Characters: Senator…
Biotechnology | COVID-19 | FDA | Life Science News | Therapeutics | Vaccine
GSK and Vir Biotechnology announced U.S. government agreements to purchase sotrovimab, a COVID-19 treatment
On Nov. 17, 2021, GlaxoSmithKline and Vir Biotechnology announced U.S. government contracts totalling approximately $1 billion (USD) to…
Pfizer submitted Emergency Use Authorization for novel COVID-19 oral antiviral candidate
On Nov. 16, 2021, Pfizer announced it announced it had submitted an Emergency Use Authorization (EUA) of its…
Health Canada Authorizes Booster Dose of Moderna’s COVID-19 Vaccine in Individuals 18 Years of Age and Older
On Nov. 15, 2021, Moderna confirmed that Health Canada authorized the use of a booster dose of the…
Phase 3 analyses showed that a single dose of REGEN-COV provides long-term protection against COVID-19
On Nov. 8, 2021, Regeneron announced that the European Commission had approved the casirivimab and imdevimab antibody cocktail,…
Cocrystal Pharma’s SARS-CoV-2 protease inhibitors ddemonstrated pan-viral activity against human common Coronaviruses, Noroviruses, Rhinoviruses and Enteroviruses
On Nov. 8, 2021, Cocrystal Pharma announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral…
Pfizer’s COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis
On Nov. 5, 2021, Pfizer announced it was investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization…
Ronapreve approved for additional indication as preventive treatment of symptomatic COVID-19 in Japan
On Nov. 5, 2021, Chugai Pharmaceutical, announced that it had obtained approval from the Ministry of Health, Labour…
Pfizer and BioNTech provided U.S. Government an additional 50 million pediatric doses of COVID-19 vaccine
On Oct. 28, 2021, Pfizer and BioNTech announced that the U.S. government had purchased 50 million more doses…
Moderna announced EMA’s CHMP recommended booster dose of Moderna’s COVID-19 vaccine in the European Union
On Oct. 25, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccine
On Oct. 21, 2021, Pfizer and BioNTech announced topline results from a Phase 3 randomized, controlled trial evaluating…